Literature DB >> 2960419

T cell subsets in multiple sclerosis. Gradients at plaque borders and differences in nonplaque regions.

K McCallum1, M M Esiri, W W Tourtellotte, J Booss.   

Abstract

This report provides a quantitative analysis of the distribution of helper-inducer T cells (H-I, LEU3A+) and cytotoxic-suppressor T cells (C-S, OKT8+) performed in a standardized fashion on material from 10 cases of multiple sclerosis. Particular attention was paid to cells at the plaque edge and to normal appearing white matter adjacent to plaques. Numbers of both the C-S and the H-I subset peaked directly at the edges of plaques, whether histopathologically active or inactive (P less than 0.01). Normal appearing areas outside active plaques had fewer C-S cells than equivalent areas outside inactive plaques (P less than 0.05). A study of three whole plaques showed that the sum of the two T cell subsets was significantly greater than the number of cells bearing the pan-T cell marker in two plaques and in two border regions. The present results support a crucial role for the balance of T cell subsets in the evolution of plaque margins. When taken together with similar findings in experimental allergic encephalomyelitis, they suggest that helper-inducer cell dominance at the border is necessary for plaque expansion while C-S dominance in non plaque areas is associated with controlled disease. In addition, they suggest either modulation of the OKT3 surface antigen or the presence of a non-T cell bearing OKT8 in association with the site of histopathological change.

Entities:  

Mesh:

Year:  1987        PMID: 2960419     DOI: 10.1093/brain/110.5.1297

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  9 in total

1.  Antiviral CD8⁺ T cells cause an experimental autoimmune encephalomyelitis-like disease in naive mice.

Authors:  Jane E Libbey; Matthew F Cusick; Ikuo Tsunoda; Robert S Fujinami
Journal:  J Neurovirol       Date:  2012-01-27       Impact factor: 2.643

2.  Characterization of a severe parenchymal phenotype of experimental autoimmune encephalomyelitis in (C57BL6xB10.PL)F1 mice.

Authors:  Michael D Carrithers; Lisette M Carrithers; Jan Czyzyk; Octavian Henegariu
Journal:  J Neuroimmunol       Date:  2007-05-18       Impact factor: 3.478

3.  Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease.

Authors:  Derrick P McCarthy; Maureen H Richards; Stephen D Miller
Journal:  Methods Mol Biol       Date:  2012

Review 4.  The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

Authors:  Andrew P Robinson; Christopher T Harp; Avertano Noronha; Stephen D Miller
Journal:  Handb Clin Neurol       Date:  2014

5.  Cathepsin D activity in human peripheral blood mononuclear leukocytes.

Authors:  C T Bever; K D Morgan; J N Whitaker
Journal:  Inflammation       Date:  1989-06       Impact factor: 4.092

Review 6.  Multiple sclerosis: a unique immunopathological syndrome of the central nervous system.

Authors:  S F Hunter; M Rodriguez
Journal:  Springer Semin Immunopathol       Date:  1995

7.  Control of lymphocyte migration into brain: selective interactions of lymphocyte subpopulations with brain endothelium.

Authors:  G Pryce; D K Male; C Sarkar
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

8.  Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

Authors:  N Kerlero de Rosbo; R Milo; M B Lees; D Burger; C C Bernard; A Ben-Nun
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  Myelin oligodendrocyte glycoprotein peptide-induced experimental allergic encephalomyelitis and T cell responses are unaffected by immunoproteasome deficiency.

Authors:  Ricardo F Frausto; Stephen J Crocker; Boreth Eam; Jason K Whitmire; J Lindsay Whitton
Journal:  J Neuroimmunol       Date:  2007-10-26       Impact factor: 3.478

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.